Ocular adverse effects associated with systemic medications: Recognition and management

Drugs

Volumn 67, Issue 1, 2007, Pages 75-93

  Santaella, Ricardo M ^a   Fraunfelder, Frederick W ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CASEY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMIODARONE; BISPHOSPHONIC ACID DERIVATIVE; CANTHAXANTHIN; CHAMOMILE; CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; DATURA EXTRACT; ECHINACEA PURPUREA EXTRACT; ETHAMBUTOL; ETIDRONIC ACID; GINKGO BILOBA EXTRACT; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; HYDROXYCHLOROQUINE; ISONIAZID; ISOTRETINOIN; NICOTINIC ACID; PAMIDRONIC ACID; PLANT EXTRACT; QUETIAPINE; RETINOID; RETINOL; RISEDRONIC ACID; SILDENAFIL; TAMOXIFEN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VIGABATRIN;

ACNE; ALLERGIC CONJUNCTIVITIS; ANTERIOR EYE CHAMBER; BLEPHAROCONJUNCTIVITIS; BLEPHAROSPASM; BLURRED VISION; BRAIN PSEUDOTUMOR; CLOSED ANGLE GLAUCOMA; COLOR VISION; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA OPACITY; CORNEA ULCER; CRANIAL NERVE PARALYSIS; CRYSTALLINE RETINOPATHY; DARK ADAPTATION; DATURA; DIPLOPIA; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG USE; DRY EYE; EDEMA; EFFUSION; ENDOCRINE OPHTHALMOPATHY; EPISCLERITIS; ERECTILE DYSFUNCTION; EXOPHTHALMOS; EYE DISCOMFORT; EYE IRRITATION; EYE MALFORMATION; EYE PAIN; EYE TOXICITY; EYEBROW; EYELASH; EYELID DISCOLORATION; EYELID DISEASE; EYELID EDEMA; GLAUCOMA; HEART ARRHYTHMIA; HERBAL MEDICINE; HIGHER PLANT; HUMAN; HYPHEMA; INTRACRANIAL HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; MALARIA; MEIBOMIAN GLAND ATROPHY; MEIBOMIAN GLAND SECRETION; MIGRAINE; MYDRIASIS; MYOPIA; NEUROPATHY; OCULAR SICCA; OCULOGYRIC CRISIS; OPTIC DISC EDEMA; OPTIC NERVE DISEASE; OPTIC NEURITIS; ORBIT EDEMA; OSMOLARITY; PAIN; PAPILLEDEMA; PATIENT CARE; PERIOCULAR SKIN PIGMENTATION; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PNEUMONIA; PREVALENCE; PUNCTATE KERATITIS; RETINA DEGENERATION; RETINA HEMORRHAGE; RETINA INJURY; RETINA MACULA EDEMA; RETINA MACULOPATHY; RETINOPATHY; RETROBULBAR OPTIC NEUROPATHY; REVIEW; RHEUMATOID ARTHRITIS; SCLERITIS; SECRETION; SEIZURE; SIDE EFFECT; SJOEGREN SYNDROME; SKIN PIGMENTATION; SUBCONJUNCTIVAL HEMORRHAGE; SUPRACHOROIDAL EFFUSION; TEAR OSMOLARITY; TERATOGENICITY; TUBERCULOSIS; UVEITIS; VASOSPASM; VISION; VISUAL ACUITY; VISUAL ADAPTATION; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; WORLD HEALTH ORGANIZATION; XEROSTOMIA; YELLOW VISION;

EYE DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYTOTHERAPY;

DATURA; ECHINACEA PURPUREA; GINKGO BILOBA;

EID: 33846279782     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767010-00006     Document Type: Review

References (102)

1. Bettman JW. Seven hundred medicolegal cases in ophthalmology. Ophthalmology 1990; 97: 1379-84
2. Brick DC. Medication errors result in costly claims for ophthalmologists. Surv Ophthalmol 1995; 40: 232-6
3. Fraunfelder FT, Fraunfelder FW. Drug-induced ocular side effects. 5th rev. ed. Boston (MA): Butterworth-Heinemann, 2001
4. Chiou GCY. Ocular toxicology. 2nd ed. Philadelphia (PA): Taylor & Francis, 1999: 43-86, 225-354
5. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of hte literature. Eye 2006 Apr; 20 (4): 407-16
6. Edwards R, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102
7. Fleish H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919-44
8. Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf 1997; 17: 197-207
9. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118: 220-4
10. Fraunfelder FW, Fraunfelder FT. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003; 135: 219-22
11. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular side effects. N Engl J Med 2003; 348: 1187-8
12. Foster CS, Forstot SL, Wilson LA. Mortality rate and rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology 1984; 91: 1253-63
13. Stewart GO, Stuckey BG, Ward LC. Iritis following intravenous pamidronate. Aust N Z J Med 1996; 26: 414-5
14. Ghose K, Waterworth R, Trolove P. Uveitis associated with pamidronate. Aust N Z J Ophthalmol 1994; 24: 320
15. Des Grottes JM, Schrooyen M, Dumon JC. Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria. Clin Rheumatol 1997; 16: 93-5
16. Medical Economics Company. Physicians' Desk Reference. 56th ed. Montvale (NJ): Medical Economics Company, 2002
17. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63
18. Fietta P, Manganelli P, Lodigiani L. Clodronate induced uveitis. Ann Rheum Dis 2003; 62: 378
19. Thiebaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386-92
20. Mbekeani JN, Slamovits TL, Schwartz BH, et al. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 1999; 117: 837-8
21. Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 2002; 86: 1443
22. Siris ES. Bisphosphonates and iritis. Lancet 1993; 341: 436-7
23. Vinas G, Olive A, Holgado S, et al. Episcleritis secondary to risedronate. Med Clin 2002 Apr 27; 118: 598-9
24. Watson PG. The nature and the treatment of scleral inflammation. Trans Ophthalmol Soc UK 1982; 102: 257-81
25. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004 Jan; 111 (1): 109-11
26. Thambi L, Kapcala LP, Chambers W, et al. Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophthalmol 2002 Aug; 120 (8): 1108
27. Banta JT, Hoffman K, Budenz DL, et al. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001 Jul; 132: 112-4
28. Bovino JA, Marcus FF. The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol 1982 Jul; 94: 99-101
29. Chirls IA, Norris JW. Transient myopia associated with vaginal sulfanilamide suppositories. Am J Ophthalmol 1984 Jul 15; 98: 120
30. Hook SR, Holladay JT, Prager TC, et al. Transient myopia induced by sulfonamides. Am J Ophthalmol 1986 Apr 15; 101: 495-6
31. Kimura R, Kasai M, Shoji K, et al. Swollen ciliary processes as an initial symptom in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1983 Mar; 95: 402
32. Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36 Suppl. 2: S95-104
33. Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997 Aug; 38: 859-80
34. Chiron C, Dulac O, Luna D, et al. Vigabatrin in infantile spasms. Lancet 1990 Feb 10; 335: 363-4
35. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999 Feb; 14: 71-4
36. Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol 1989; 27: 3-11S
37. Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional crossover study. Epilepsy Res 1996; 25: 257-62
38. Elke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-1
39. Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784-94
40. Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922-66
41. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin. Neurology 1999; 53: 2082-7
42. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792-8
43. Harding GFA, Wild JM, Robertson KA, et al. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 2000; 55: 347-52
44. Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48: 60-4
45. Mustafa BA. Diversity of GABA receptors in the vertebrate outer retina. Trends Neurosci 1995; 85: 118-20
46. Pow DV, Baldridge W, Crook DK. Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy. Neuroscience 1996; 73: 1129-43
47. Butler WH. The neuropathology of vigabatrin. Epilepsia 1989; 30 Suppl. 3: S15-17
48. Neal MJ, Cunningham JR, Shah MA, et al. Immunocytochemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett 1989; 89: 29-32
49. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792-8
50. Kaufman KR, Lepore FE, Keyser BJ. Visual fields and tiagabine: a quandary. Seizure 2001; 10: 525-9
51. Krauss G, Johnson M, Sheth S, et al. A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatr 2003; 74: 339-43
52. Nousiainen I, Mäntyjärvi M, Kälviäinen R. Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine. Clin Drug Invest 2000; 20: 393-400
53. Sorri I, Kalviainen R, Mantyjarvi M. Color vision and contrast sensitivity in epilepsy patients treated with initial tiagabine monotherapy. Epilepsy Res 2005 Dec; 67 (3): 101-7
54. Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology 2004 Jun; 111 (6): 1248-50
55. Fraunfelder FT, Fraunfelder FW. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001; 132 (3): 299-305
56. Cchroeter T, Lanvers C, Herding H, et al. Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia. Med Pediatr Oncol 2000; 34: 284-6
57. Sano F, Tsuji K, Kunika N, et al. Pseudotumor cerebri in a patient with acute promyelocytic leukemia during treatment with all-trans-retinoic acid. Intern Med 1998; 37 (6): 546-9
58. Tiamkao S, Sirijirachai C. Pseudotumor cerebri caused by all-trans-retinoic acid: a case report. J Med Assoc Thai 2000; 83 (11): 1420-3
59. Fraunfelder FW, Fraunfelder FT. Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol 2004 Sep; 24 (3): 214-6
60. Guirgis MF, Lueder GT. Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management. J AAPOS 2003; 7 (6): 432-4
61. Morrice G, Havener WH, Kapetansky F. Vitamin A intoxication as a cause of pseudotumor cerebri. JAMA 1960; 173: 1802-5
62. Jacobson DM, Berg R, Wall M, et al. Serum vitamin A concentration is elevated in idiopathic intracranial hypertension. Neurology 1999; 53 (5): 1114-8
63. Visani G, Manfroi S, Tosi P, et al. All-trans-retinoic acid and pseudotumor cerebri. Leuk Lymphoma 1996; 23: 437-42
64. Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis 1988; 42: 399-400
65. Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis 1995; 55 (3): 165-8
66. Donahue SP. Recurrence of idiopathic intracranial hypertension after weight loss: the carrot craver. Am J Ophthalmol 2000; 130 (6): 850-1
67. Hoffner SE, Kallenius G, Beezer AE, et al. Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex. Acta Leprol 1989; 7 Suppl. 1: 195-9
68. Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002; 17 (1): 29-32
69. Kaimbo WK, Bifuko ZA, Longo MB, et al. Color vision in 42 Congolese patients with tuberculosis receiving ethambutol treatment. Bull Soc Belge Ophtalmol 2002; 284: 57-61
70. Karmon G. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. Ann Ophthalmol 1979; 11: 1013
71. Kass I, Mandel W. Isoniazid as a cause of optic neuritis and atrophy. JAMA 1957; 164: 1740-3
72. Kozak SF, Inderlied CB, Hsu HY, et al. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis 1998; 30: 83-7
73. Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002 17(1):29-32
74. Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987; 62: 702-17
75. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999; 127 (5): 610-2
76. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998; 42: 360-6
77. Marmor MF, Carr RE, Easterbrook E, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109: 1377-82
78. Shroyer NF, Lewis RA, Lupski JR. Analysis of the ABCR (ABCA4) gene in 4 aminoquinoline retinopathy: is retinal toxicity by chloriquinine and hydroxychlorquine related to Stargardt disease? Am J Ophthalmol 2001 Jun; 131 (6): 761-6
79. Fraunfelder FW. Visual side effects associated with erectile dysfunction agents. Am J Ophthalmol 2005 Oct; 140 (4): 723-4
80. Reivich M, Holling HE, Roberts B, et al. Reversal of blood flow through the vertebral artery and its effect on cerebral circulation. N Engl J Med 1961 Nov 2; 265: 878-85
81. Laties AM, Fraunfelder FT. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthalmol Soc 1999; 97: 115-28
82. Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125: 493-501
83. Gorin MB, Costantino JP, Kulacoglu DN, et al. Is tamoxifen a risk factor for retinal vaso-occlusive disease? Retina 2005; 25: 523-6
84. Fraunfelder FW, Solomon J, Mehelas TJ. Ocular side effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol 2006; 124: 277-279
85. Coulter DM, Clark DWJ, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 2003; 327: 1214-5
86. Haefliger IO, Meyer P, Flammer J, et al. The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology. Surv Ophthalmol 1994; 39: 123-32
87. Tullio CJ. Ibuprofen-induced visual disturbance. Am J Hosp Pharm 1981; 38: 1362
88. Nicastro NJ. Visual disturbances associated with over-the-counter ibuprofen in three patients. Ann Ophthalmol 1989; 21: 447-50
89. Bovino JA, Marcus FF. The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol 1982; 94: 99-101
90. Lutz EG. Allergic conjunctivitis due to diazepam. Am J Psych 1975; 132 (5): 548
91. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995; 79: 54-6
92. Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol 1973; 76: 500-10
93. Jampol LM. Niacin maculopathy. Ophthalmology 1988; 95: 1704-5
94. Fraunfelder FW. Ocular side effects associated with dietary supplements and herbal medicines. Drugs Today 2005; 41 (8): 537-45
95. Physicians' Desk Reference for herbal medicines. 2nd rev. ed. Montvale (NJ): Thomson Healthcare, 2004
96. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998 Nov 11; 289 (18): 1569-75
97. Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol 2004 Oct; 138 (4): 639-47
98. Espaillat A. Canthaxanthine retinopathy. Arch Ophthalmol 1999; 113: 412-3
99. Subiza J. Allergic conjunctivitis to chamomile tea. Ann Allergy Asthma Immunol 1990; 65: 127-32
100. Blumenthal M, editor. The complete German Commission E monographs therapeutic guide to herbal medicines. Austin (TX): American Botanical Council, 1998
101. Grimm W, Muller H. A randomized controlled trial of the effect of fluid extract of echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 1999 Feb; 106: 138-43
102. Dobbins KR, Saul RF. Transient visual loss after licorice ingestion. J Neurophthalmol 2000 Mar; 20: 38-41